Navigation Links
Potential new approach to treat cognitive impairments in schizophrenia
Date:9/24/2007

Philadelphia, PA, September 24, 2007 -- A new study reports important evidence for a potential new treatment approach for those diagnosed with schizophrenia. Schizophrenia is considered one of the most devastating of the major psychiatric disorders, which has three distinct facets, often referred to as positive (hallucinations, delusions), negative (blunted emotions, reduced capacity for pleasure), and cognitive (impairments in attention, memory, and problem-solving) symptoms. The cognitive impairments associated with schizophrenia are the aspect of this disorder most strongly associated with the inability to function in the workplace.

The medications currently approved to treat schizophrenia block a subclass of dopamine receptors (dopamine D2 receptors). They have limited efficacy in treating the negative and cognitive symptoms of this disorder and they are frequently associated with significant side effects. Hence, there is an acute need to develop alternative treatments for schizophrenia that have fewer side effects and are more effective in treating cognitive and negative symptoms of the disorder, according to the authors of this study, scheduled for publication in Biological Psychiatry on October 1st.

Multidisciplinary work has led to the emergence of the glutamate system as a promising therapeutic target for [the] treatment of schizophrenia, says Bita Moghaddam, Ph.D., the corresponding author on the study. Abnormal function of brain circuits that utilize glutamate as a chemical messenger, particularly in brain regions including the prefrontal cortex and hippocampus, has been implicated in the cognitive deficits associated with schizophrenia. The glutamate-related circuit dysfunction associated with schizophrenia may be modeled, to a meaningful extent, by blocking the NMDA subtype of glutamate receptor. The authors now report that by administering 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide or CDPPB, a drug that stimulates another type of glutamate receptor, the metabotropic glutamate 5 receptor (mGluR5), they can normalize abnormalities in prefrontal cortical function produced by blocking the NMDA glutamate receptor. In other words, CDPPB appears to treat an abnormality in brain function that may resemble aspects of schizophrenia.

Dr. Moghaddam comments, This work is significant because it shows that in an awake behaving mammal (as opposed to in tissue cultures or similar preparation), activation of these receptors has a normalizing effect on the spontaneous activity of prefrontal cortex neurons. John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, adds, These exciting new data provide important new evidence supporting the testing of mGluR5 stimulating medications for the treatment of schizophrenia, particularly cognitive deficits associated with impairments in the function of the prefrontal cortex. It would be very interesting to know whether this class of medication reduces the transient impairments in cognitive function associated with the administration of NMDA receptor blockers to humans. Although the authors acknowledge that much more research is needed to evaluate the clinical impact of this treatment approach, this study indicates a promising therapeutic potential that could ultimately result in making improved treatments available to patients struggling with this illness.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Unwed mothers find it difficult to attract potential life partner
6. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
7. Unpasteurised juices found to be potential health hazards
8. The many facets of milk and its health potential
9. Artificial sweetener, Aspartame, may be the potential cause of lymphoma, leukaemia
10. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
11. Alcohol a potential carcinogen: knocking on the door: pay heed!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... C. (PRWEB) , ... February 13, 2016 , ... Hidden Cypress in Sun City is ... area of facial plastic surgery. Dr. Frederick Weniger will be hosting this educational ... at this event, and there will be special pricing on offers. In addition, prizes will ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker ... Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and ... hydrated before the big event. The invitation-only gifting suite, held this year at the ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... 11, 2016 Laboratory glassware and ... laboratories. These may range from microscope slides to large ... made from borosilicate glass because of its low weight ... other hand, started gaining popularity over the past decade ... replace glass with plastic in several applications due to ...
Breaking Medicine Technology: